Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca G Guidotti

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Journal of Hepatology|June 8, 2013
Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinomaGiovanni Sitia, Matteo Iannacone, Luca G Guidotti
Gastroenterology|September 12, 2020
Is It Time to Recommend Low-Dose Aspirin Treatment for the Prevention of Hepatocellular Carcinoma?Luca G Guidotti, Carlo La Vecchia, Massimo Colombo
Current Opinion in Immunology|July 18, 2015
Host-virus interactions in hepatitis B virus infectionLuca G Guidotti, Masanori Isogawa, Francis V Chisari
Hepatology (Baltimore, Md.)|March 7, 2022
Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?Luca G Guidotti, Carlo La Vecchia, Massimo Colombo
Journal of Hepatology|February 24, 2007
HBV pathogenesis in animal models: recent advances on the role of plateletsMatteo Iannacone, Giovanni Sitia, Zaverio M Ruggeri, et al.
Clinical and Vaccine Immunology : CVI|September 21, 2007
Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirusMatteo Iannacone, Giovanni Sitia, Iñigo Narvaiza, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2002
Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic miceKiminori Kimura, Kazuhiro Kakimi, Stefan Wieland, et al.
Journal of Virology|October 9, 2002
Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic miceKiminori Kimura, Kazuhiro Kakimi, Stefan Wieland, et al.
Journal of Leukocyte Biology|August 29, 2006
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic miceGiovanni Sitia, Matteo Iannacone, Susanne Müller, et al.
Science Signaling|February 22, 2022
Arenaviral infection causes bleeding in mice due to reduced serotonin release from plateletsRoberto Aiolfi, Giovanni Sitia, Matteo Iannacone, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Journal of Hepatology|June 8, 2013
Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinomaGiovanni Sitia, Matteo Iannacone, Luca G Guidotti
Gastroenterology|September 12, 2020
Is It Time to Recommend Low-Dose Aspirin Treatment for the Prevention of Hepatocellular Carcinoma?Luca G Guidotti, Carlo La Vecchia, Massimo Colombo
Current Opinion in Immunology|July 18, 2015
Host-virus interactions in hepatitis B virus infectionLuca G Guidotti, Masanori Isogawa, Francis V Chisari
Hepatology (Baltimore, Md.)|March 7, 2022
Low-dose aspirin reduces the risk of HBV-associated HCC even when administered short-term: Too good to be true?Luca G Guidotti, Carlo La Vecchia, Massimo Colombo
Journal of Hepatology|February 24, 2007
HBV pathogenesis in animal models: recent advances on the role of plateletsMatteo Iannacone, Giovanni Sitia, Zaverio M Ruggeri, et al.
Clinical and Vaccine Immunology : CVI|September 21, 2007
Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirusMatteo Iannacone, Giovanni Sitia, Iñigo Narvaiza, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 23, 2002
Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic miceKiminori Kimura, Kazuhiro Kakimi, Stefan Wieland, et al.
Journal of Virology|October 9, 2002
Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic miceKiminori Kimura, Kazuhiro Kakimi, Stefan Wieland, et al.
Journal of Leukocyte Biology|August 29, 2006
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic miceGiovanni Sitia, Matteo Iannacone, Susanne Müller, et al.
Science Signaling|February 22, 2022
Arenaviral infection causes bleeding in mice due to reduced serotonin release from plateletsRoberto Aiolfi, Giovanni Sitia, Matteo Iannacone, et al.
Pageof 7